Long Non-coding RNA HAGLROS Promotes the Development of Diffuse Large B-cell Lymphoma Via Suppressing MiR-100

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2021 Dec 10

PMID 34888946

Citations 5

Authors

Ling Shu

Kun Guo

Zeng-Hua Lin

Hong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Long non-coding RNAs (lncRNAs), a vital component of functional regulators, are involved in various human cancers development, including diffuse large B-cell lymphoma (DLBCL). In particular, lncRNA HAGLROS has been reported to be associated with several types of cancer in humans. Nevertheless, the role of HAGLROS in DLBCL has yet to be described.

Methods: The HAGLROS expression patterns and its relationship with clinicopathological features and survival were investigated in DLBCL patients. CCK-8 and transwell assays were used to analyze the cell proliferation, migration, and invasion capacities. AGO2-RIP, dual-luciferase assay, RT-qPCR, and rescue experiments were fulfilled to measure the physical interaction between HAGLROS and miR-100. Xenograft assay was conducted to test tumor growth ability.

Results: HAGLROS was upregulated in DLBCL tissues and cells, and closely associated with advanced clinicopathological features. Upregulation of HAGLROS resulted in poor survival outcomes in DLBCL patients. In addition, HAGLROS knockdown inhibited the proliferation, migration, and invasion of DLBCL cells in vitro. Further experiments revealed that HAGLROS negatively regulated the expression of miR-100 in DLBCL, and the expression of miR-100 and HAGLROS showed an inverse correlation in DLBCL tissues. HAGLROS functioned as a competing endogenous RNA for miR-100 in DLBCL cells, and miR-100 overexpression abolished the oncogenic effects of HAGLROS upregulation on DLBCL progression. Besides, in-vivo assays revealed that HAGLROS knockdown suppressed tumor growth in nude mice.

Conclusion: HAGLROS overexpression contributes to DLBCL development and poor prognosis via targeting miR-100, which could be a potential prognostic biomarker and therapeutic target for DLBCL patients.

Citing Articles

miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).

Zhang L, Zhang J, Zhang X, Liu S, Qi C, Gao S Int J Mol Med. 2025; 55(4).

PMID: 40017111 PMC: 11875724. DOI: 10.3892/ijmm.2025.5508.

TGFBI regulates the TGF-β pathway to affect the malignant progression and cisplatin sensitivity in diffuse large B-cell lymphoma.

Wu L, Jiang L, Zhou Y, Zheng W, Feng A, Guo H Ann Hematol. 2025; .

PMID: 39856252 DOI: 10.1007/s00277-025-06208-1.

LncRNA HAGLROS promotes breast cancer evolution through miR-135b-3p/COL10A1 axis and exosome-mediated macrophage M2 polarization.

Meng Z, Zhang R, Wu X, Piao Z, Zhang M, Jin T Cell Death Dis. 2024; 15(8):633.

PMID: 39198393 PMC: 11358487. DOI: 10.1038/s41419-024-07020-x.

Upregulation and the clinical significance of KCNQ1OT1 and HAGLROS lncRNAs in papillary thyroid cancer: An observational study.

Mutlu Icduygu F, Akgun E, Ozgoz A, Hekimler Ozturk K, Sengul D, Alp E Medicine (Baltimore). 2023; 102(29):e34379.

PMID: 37478216 PMC: 10662889. DOI: 10.1097/MD.0000000000034379.

Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.

Khanmohammadi S, Fallahtafti P J Cell Mol Med. 2023; 27(14):1928-1946.

PMID: 37246627 PMC: 10339099. DOI: 10.1111/jcmm.17795.

References

Zhao L, Liu Y, Zhang J, Liu Y, Qi Q . LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019; 10(10):731. PMC: 6769008. DOI: 10.1038/s41419-019-1886-5. View

Pasqualucci L, Dalla-Favera R . Genetics of diffuse large B-cell lymphoma. Blood. 2018; 131(21):2307-2319. PMC: 5969374. DOI: 10.1182/blood-2017-11-764332. View

Shi X, Cui Z, Liu X, Wu S, Wu Y, Fang F . LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway. Biochem Biophys Res Commun. 2019; 510(4):594-600. DOI: 10.1016/j.bbrc.2019.01.105. View

Wu P, Dai Z, Liu W, Zhao Z, Kong Y . Elevated long noncoding RNA HAGLROS expression correlates with clinical progression and prognosis in osteosarcoma. Eur Rev Med Pharmacol Sci. 2019; 23(4):1428-1433. DOI: 10.26355/eurrev_201902_17099. View

Shu L, Guo K, Lin Z, Liu H . Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100. J Clin Lab Anal. 2021; 36(1):e24168. PMC: 8761451. DOI: 10.1002/jcla.24168. View

Gutschner T, Diederichs S . The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012; 9(6):703-19. PMC: 3495743. DOI: 10.4161/rna.20481. View

Yang M, Zhai Z, Zhang Y, Wang Y . Clinical significance and oncogene function of long noncoding RNA HAGLROS overexpression in ovarian cancer. Arch Gynecol Obstet. 2019; 300(3):703-710. DOI: 10.1007/s00404-019-05218-5. View

Wei H, Hu J, Pu J, Tang Q, Li W, Ma R . Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095/ATG12 axis in hepatocellular carcinoma cells. Int Immunopharmacol. 2019; 73:72-80. DOI: 10.1016/j.intimp.2019.04.049. View

Wang W, Yu D, Zhong M . LncRNA HAGLROS accelerates the progression of lung carcinoma via sponging microRNA-152. Eur Rev Med Pharmacol Sci. 2019; 23(15):6531-6538. DOI: 10.26355/eurrev_201908_18538. View

10.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi P . A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell. 2011; 146(3):353-8. PMC: 3235919. DOI: 10.1016/j.cell.2011.07.014. View

11.

Bhan A, Soleimani M, Mandal S . Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15):3965-3981. PMC: 8330958. DOI: 10.1158/0008-5472.CAN-16-2634. View

12.

Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang Z . miRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR. Mol Cancer Ther. 2012; 12(2):207-19. DOI: 10.1158/1535-7163.MCT-12-0273. View

13.

Zhu L, Mei M . Interference of long non-coding RNA HAGLROS inhibits the proliferation and promotes the apoptosis of ovarian cancer cells by targeting miR-26b-5p. Exp Ther Med. 2021; 22(2):879. PMC: 8237406. DOI: 10.3892/etm.2021.10311. View

14.

Wang Q, Lian G, Song Y, Huang Y, Gong Y . LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 2019; 231:116335. DOI: 10.1016/j.lfs.2019.03.040. View

15.

Qian C, Li L, Huang H, Yang H, Wu D . MYC-regulated lncRNA NEAT1 promotes B cell proliferation and lymphomagenesis via the miR-34b-5p-GLI1 pathway in diffuse large B-cell lymphoma. Cancer Cell Int. 2020; 20:87. PMC: 7081629. DOI: 10.1186/s12935-020-1158-6. View

16.

Bartonicek N, Maag J, Dinger M . Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016; 15(1):43. PMC: 4884374. DOI: 10.1186/s12943-016-0530-6. View

17.

Chen Y, Shen T, Ding X, Cheng L, Sheng L, Du X . HAGLROS is overexpressed and promotes non-small cell lung cancer migration and invasion. Jpn J Clin Oncol. 2020; 50(9):1058-1067. DOI: 10.1093/jjco/hyaa075. View

18.

Ma X, Zhou J, Mo H, Ying Y . Association of miR-100 expression with clinicopathological features and prognosis of patients with lung cancer. Oncol Lett. 2019; 18(2):1318-1322. PMC: 6607036. DOI: 10.3892/ol.2019.10393. View

19.

Fatima R, Akhade V, Pal D, Rao S . Long noncoding RNAs in development and cancer: potential biomarkers and therapeutic targets. Mol Cell Ther. 2015; 3:5. PMC: 4469312. View

20.

Zhao C, Jiao Y, Zhang Y, Ning J, Zhang Y, Xu J . Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/β-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis. 2019; 10(4):252. PMC: 6420660. DOI: 10.1038/s41419-019-1479-3. View